Live, attenuated influenza virus (LAIV) vehicles are strong inducers of immunity toward influenza B virus
- PMID: 18708106
- PMCID: PMC2547490
- DOI: 10.1016/j.vaccine.2008.07.086
Live, attenuated influenza virus (LAIV) vehicles are strong inducers of immunity toward influenza B virus
Abstract
Historically, vaccines developed toward influenza viruses of the B type using methodologies developed for influenza A viruses as a blueprint have not been equally efficacious or effective. Because most influenza research and public attention concerns influenza A viruses, these shortcomings have not been adequately addressed. In this manuscript, we utilized different influenza vaccine vehicles to compare immunogenicity and protection in mice and ferrets after vaccination against an influenza B virus. We report that plasmid DNA vaccines demonstrate low immunogenicity profiles and poor protection compared to either whole, inactivated influenza virus (IIV) or, live, attenuated influenza virus (LAIV) vaccines. When mixed prime:boost regimens using LAIV and IIV were studied, we observed a boosting effect in mice after priming with LAIV that was not seen when IIV was used as the prime. In ferrets LAIV induced high antibody titers after a single dose and provided a boost in IIV-primed animals. Regimens including LAIV as a prime demonstrated enhanced protection, and adjuvantation was required for efficacy using the IIV preparation. Our results differ from generally accepted influenza A virus vaccine models, and argue that strategies for control of influenza B virus should be considered separately from those for influenza A virus.
Figures
Comment in
-
Valuable data surrounding the priming and boosting abilities of various vaccine technologies.Vaccine. 2009 Jan 14;27(3):349. doi: 10.1016/j.vaccine.2008.11.016. Epub 2008 Nov 21. Vaccine. 2009. PMID: 19027811 No abstract available.
References
-
- Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003 Jan 8;289(2):179–86. - PubMed
-
- Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004 Sep 15;292(11):1333–40. - PubMed
-
- La Montagne, Noble GR, Quinnan GV, Curlin GT, Blackwelder WC, Smith JI, et al. Summary of clinical trials of inactivated influenza vaccine - 1978. Rev Infect Dis. 1983 Jul;5(4):723–36. - PubMed
-
- Meiklejohn G. Viral respiratory disease at Lowry Air Force Base in Denver, 1952-1982. J Infect Dis. 1983 Nov;148(5):775–84. - PubMed
-
- Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine. 2003 May 1;21(16):1769–75. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
